AVS is an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease. It was founded in 2018 by Hitinder Gurm, M.D., Interventional Cardiologist and Chief Clinical Officer at University of Michigan, and Robert Chisena, Ph.D., Chief Technical Officer at AVS. It is redefining interventional therapy for severely calcified lesions with the Pulse IVL System, which uses a novel pulsatile mechanism of action to shatter calcium and expand narrowed vessels, all with a single device.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/05/23 | $20,000,000 | Series B |
BioStar Capital | undisclosed |
| 04/04/23 | $8,800,000 | Series B |
BioStar Capital CUE Growth Partners | undisclosed |
